Benjamin Vidal is a research engineer for the biopharmaceutical company Theranexus, which is developing innovative drug candidates to be used in the treatment of CNS disorders. He is using in vivo neuroimaging techniques such as positron emission tomography, functional magnetic resonance imaging and functional ultrasound in order to study brain pharmacology and animal models of neurological diseases.